[go: up one dir, main page]

AR057964A1 - Polimorfos de un inhibidor de c-met/hgfr - Google Patents

Polimorfos de un inhibidor de c-met/hgfr

Info

Publication number
AR057964A1
AR057964A1 ARP060105349A ARP060105349A AR057964A1 AR 057964 A1 AR057964 A1 AR 057964A1 AR P060105349 A ARP060105349 A AR P060105349A AR P060105349 A ARP060105349 A AR P060105349A AR 057964 A1 AR057964 A1 AR 057964A1
Authority
AR
Argentina
Prior art keywords
polymorphes
met
hgfr inhibitor
polymorphs
mammals
Prior art date
Application number
ARP060105349A
Other languages
English (en)
Inventor
Jingrog Jean Cui
Michelle Bich Tran-Duble
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057964(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR057964A1 publication Critical patent/AR057964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a polimorfos de (R)-3-[1-(2,6-dicloro-3-fluoro-fenil)-etoxi]-5-(1-piperidin-4-il-1H-pirazol-4-il)-piridin-2-ilamina que son utiles en el tratamiento del crecimiento celular anormal, tal como cáncer, en mamíferos. La presente también se refiere a composiciones que incluyen tales sales y polimorfos, y a métodos de uso de tales composiciones en el tratamiento del crecimiento celular anormal en mamíferos, especialmente seres humanos.
ARP060105349A 2005-12-05 2006-12-04 Polimorfos de un inhibidor de c-met/hgfr AR057964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74267605P 2005-12-05 2005-12-05

Publications (1)

Publication Number Publication Date
AR057964A1 true AR057964A1 (es) 2007-12-26

Family

ID=38123249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105349A AR057964A1 (es) 2005-12-05 2006-12-04 Polimorfos de un inhibidor de c-met/hgfr

Country Status (19)

Country Link
US (1) US8217057B2 (es)
EP (1) EP1963302B1 (es)
JP (1) JP4663619B2 (es)
KR (1) KR101146852B1 (es)
CN (1) CN101326175B (es)
AR (1) AR057964A1 (es)
AU (1) AU2006323025B2 (es)
CA (1) CA2632283C (es)
DK (1) DK1963302T3 (es)
ES (1) ES2402419T3 (es)
IL (1) IL191971A (es)
NZ (1) NZ568289A (es)
PL (1) PL1963302T3 (es)
PT (1) PT1963302E (es)
RU (1) RU2387650C2 (es)
SI (1) SI1963302T1 (es)
TW (1) TWI389902B (es)
WO (1) WO2007066185A2 (es)
ZA (1) ZA200804374B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578066C (en) * 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
BRPI0619424B1 (pt) * 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
EP2569315A1 (en) 2010-05-14 2013-03-20 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
JP4918630B1 (ja) * 2010-08-20 2012-04-18 中外製薬株式会社 ４環性化合物を含む組成物
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN107090038A (zh) 2011-06-30 2017-08-25 霍夫曼-拉罗奇有限公司 抗c‑met抗体配制剂
EP2620140A1 (en) 2012-01-26 2013-07-31 ratiopharm GmbH Crizotinib containing compositions
BR112014022106B1 (pt) 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
US9651555B2 (en) 2012-09-24 2017-05-16 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
CN106456651A (zh) 2014-04-25 2017-02-22 中外制药株式会社 以高用量含有四环性化合物的制剂
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016169030A1 (zh) * 2015-04-23 2016-10-27 正大天晴药业集团股份有限公司 吡啶胺化合物的富马酸盐及其晶体
CN106220644B (zh) 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
EP3355902B1 (en) 2015-09-30 2022-04-13 Merck Patent GmbH Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
US11400155B2 (en) 2016-05-20 2022-08-02 Biohaven Therapeutics Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN108727337A (zh) * 2018-07-03 2018-11-02 无锡富泽药业有限公司 一种克唑替尼中间体的制备方法
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DK1255740T3 (da) 2000-02-16 2006-02-06 Neurogen Corp Substituerede arylpyraziner
EP1308441B1 (en) * 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
US7230098B2 (en) * 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
CA2578066C (en) * 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
BRPI0619424B1 (pt) * 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos

Also Published As

Publication number Publication date
KR20080074950A (ko) 2008-08-13
CN101326175A (zh) 2008-12-17
AU2006323025A1 (en) 2007-06-14
IL191971A0 (en) 2011-08-01
PL1963302T3 (pl) 2013-06-28
HK1126477A1 (en) 2009-09-04
RU2387650C2 (ru) 2010-04-27
RU2008120338A (ru) 2010-01-20
SI1963302T1 (sl) 2013-04-30
WO2007066185A3 (en) 2008-01-24
BRPI0619420A2 (pt) 2011-10-04
EP1963302A2 (en) 2008-09-03
CA2632283C (en) 2011-06-21
PT1963302E (pt) 2013-04-09
ZA200804374B (en) 2009-12-30
WO2007066185A2 (en) 2007-06-14
IL191971A (en) 2013-05-30
ES2402419T3 (es) 2013-05-03
TW200730522A (en) 2007-08-16
JP2007153893A (ja) 2007-06-21
DK1963302T3 (da) 2013-04-02
AU2006323025B2 (en) 2012-07-05
CA2632283A1 (en) 2007-06-14
CN101326175B (zh) 2012-07-18
US8217057B2 (en) 2012-07-10
EP1963302B1 (en) 2013-02-27
US20080293769A1 (en) 2008-11-27
NZ568289A (en) 2011-06-30
TWI389902B (zh) 2013-03-21
KR101146852B1 (ko) 2012-05-16
JP4663619B2 (ja) 2011-04-06

Similar Documents

Publication Publication Date Title
AR057964A1 (es) Polimorfos de un inhibidor de c-met/hgfr
GT200900003A (es) Fungicidas
CR20120213A (es) Métodos para el tratamiento del cáncer usando antagonistas de notch
AR056832A1 (es) Procedimiento para tratar el crecimiento celular anormal
AR063127A1 (es) Metodo para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
TN2010000305A1 (en) Pyrrolopyrimidines and pyrrolopyridines
CO6351786A2 (es) Inkibidores de la cinasa map p38
CO6630147A2 (es) Modificador del sabor dulce
ECSP099803A (es) Derivados de bencimidazol
PE20150626A1 (es) Modificador del sabor dulce
PA8740901A1 (es) Compuestos organicos
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CL2009000742A1 (es) Forma solida cristalina de clorhidrato de bendamustina, designada como forma 1; composicion farmaceutica que la comprende; metodo de preparacion de la composicion farmaceutica; y uso en el tratamiento de leucemia linfocitica cronica, enfermedad de hodgkin, linfoma no hodgkiniano, mieloma multiple o cancer de mama.
CL2009000651A1 (es) Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer.
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
TN2010000167A1 (en) Organic compounds
MX2019005232A (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
ATE522249T1 (de) Organische verbindungen
CO2017003011A2 (es) Derivados de benzodiazepina citotóxicos
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
ECSP11010816A (es) Nuevos Compuestos
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
GT200900045A (es) Sales de bencimidazolilo piridilo eteres y las formulaciones del mismo

Legal Events

Date Code Title Description
FC Refusal